This trial is evaluating whether CNTX-6970 will improve 2 primary outcomes and 12 secondary outcomes in patients with Arthrosis. Measurement will happen over the course of 1 Week.
This trial requires 150 total participants across 4 different treatment groups
This trial involves 4 different treatments. CNTX-6970 is the primary treatment being studied. Participants will be divided into 2 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"Results from a recent paper illustrates the extent to which data are readily available about arthritis, and offers specific insight into the demographics, management and management outcome of this disease in the US." - Anonymous Online Contributor
"Factors that are associated with the development of [osteoarthritis](https://www.withpower.com/clinical-trials/osteoarthritis), knee, in the elderly are gender, age and ethnicity as well as preexisting arthritis or other joint problems. While some predisposing factors can be identified, the precise causes of osteoarthritis are not yet fully understood, but are thought to result from several possible pathways." - Anonymous Online Contributor
"Patients suffering from knee osteoarthritis of both knee joints may benefit from treatment by a multifaceted and complex treatment strategy with conservative treatment strategies, especially by physiotherapy, non-steroidal anti-inflammatory drugs, and analgesics. Patients with high-intensity pain may benefit from an injection therapy (especially a mixture of glucocorticoids with local anaesthetic)." - Anonymous Online Contributor
"One of the most important and well-researched aspects for the treatment of knee OA is physiotherapy. In order to increase the effects of these therapies, the number of physiotherapists present in the clinic is essential. It is also important for clinical assessments to be done and repeated at least once per week during the treatment. Treatment approaches like intra-articular injections, local hyperbaric oxygen therapy, or ultrasound are other potential approaches in knee OA. Surgery is another potential treatment option for knee OA. However, it is only implemented as the last resort." - Anonymous Online Contributor
"According to the American Academy of Osteopathic Family Physicians, the diagnosis of osteoarthritis, knee, is a condition that causes pain and stiffness, swelling, weakness, and possibly discolouration to one or more joint(s). These symptoms can cause significant functional impairment and are more common in older individuals." - Anonymous Online Contributor
"Many people with [knee [osteoarthritis](https://www.withpower.com/clinical-trials/osteoarthritis)](https://www.withpower.com/clinical-trials/knee-osteoarthritis) do not have symptoms and may not report symptoms to a healthcare provider until the joint becomes very painful and/or they experience limitations in their ability to walk or do other activities of daily living. As a result, diagnosis of knee osteoarthritis is often delayed, and treatment options for knee arthritis may be delayed (if treatment is received at all). The primary physical symptom of knee arthritis that correlates with worse functional outcomes (i.e., decreased quality of life) is knee pain (also known as osteoarthritis-related pain or joint stiffness). These symptoms are also associated with pain on the lesser extremities, although functional limitation is not as strong." - Anonymous Online Contributor
"In OA, the chondrocyte-expressed CCNT7 gene was expressed. Knockdown of endogenous CCNT7 expression in OA chondrocytes reduced in vitro proliferation rates and accelerated chondrocyte phenotype maturation. Results from a recent clinical trial suggest the potential role of CCNT7 in the pathogenesis of OA and the potential for CCNT7 inhibition as a therapeutic strategy for the OA process." - Anonymous Online Contributor
"In a recent study, findings provides evidence of the clinical efficacy of p4565 in this patient population. Given the significant and sustained anti-oxidant and anti-cytotoxic properties, p4565 has the potential for future clinical application in managing ROS-mediated tissue damage, a common feature of many arthritis-related disorders." - Anonymous Online Contributor
"Findings from a recent study do not indicate Cntx-6970 is advantageous compared to placebo in the treatment of OA, although it still results in improvements in some domains of knee pain, function, and patient satisfaction. Further research on this medication to further understand the contribution it may make to improving outcomes in OA patients is warranted." - Anonymous Online Contributor
"[When a patient has osteoarthritis, more than one factor generally is involved]:  pain and/or stiffness, which often is multifactorial;  joint space narrowing, which is the primary symptom observed;  alteration of the joint biomechanics;  deterioration of the articular cartilage; and  changes in surrounding cartilage and osteophyte formation. (http://www.hicc.edu/pdf/Osteoarthritis.pdf." - Anonymous Online Contributor
"Common side effects (greater than 1% incidence) include pain, erythema, skin redness, and hypertrichosis. The most commonly reported side effect of celecoxib in patients with osteoarthritis of the knee was upper respiratory tract irritation (5%). This is similar to other NSAIDs (e.g., diclofenac). Side effects are most commonly mild, but often appear sooner among women than in men or among users of extended-release products than with immediate-release products. Women and smokers are at increased risk for more severe or frequent side effects." - Anonymous Online Contributor
"There is ample evidence that OA is a common problem and that it leads to low scores on the self-administered health survey, EQ-5D and VAS scales. Thus a direct comparison of the effect of interventions for [osteoarthritis](https://www.withpower.com/clinical-trials/osteoarthritis) on the above measures of health is very straightforward. However the results have to be interpreted in the light of the wide variations that exist in the extent to which different clinical trials and populations with different levels of disease severity included in the comparisons." - Anonymous Online Contributor